Akums Drugs Restores 100% Haridwar Ops After Four-Day Labour Unrest

Akums Drugs and Pharmaceuticals Limited has fully restored manufacturing operations at its Haridwar sites, with all affected units resuming at 100% capacity with effect from May 18, 2026. This follows a series of updates issued by the company on May 14 and May 16, 2026, regarding a partial disruption caused by an industry-wide labour unrest triggered by a review of minimum wages by state authorities. The disruption impacted all major industrial towns in Uttarakhand, though operations at other manufacturing units remained stable throughout the period.

Restoration of Operations

The partial disruption in production at the Haridwar sites lasted for four days, during which operations had been restored to over 70% capacity as of May 16, 2026. All manufacturing operations at the affected sites of the company and its subsidiaries, situated in the state of Uttarakhand, have now been successfully resumed at 100% operations capacity with effect from May 18, 2026. The company stated it is hopeful to make up for the production loss in the coming weeks.

Impact Assessment

The four-day disruption resulted in delayed supply of approximately INR 20 Cr. There was no damage to the property of the company. Given the absence of property damage and the nature of the disruption, no insurance claim will be made for the said disruption of operations. Key details regarding the impact are outlined below:

Parameter	Details
Operations Resumed	100% at Haridwar sites
Date of Full Resumption	May 18, 2026
Duration of Disruption	Four days
Delayed Supply	Approx. INR 20 Cr
Property Damage	None
Insurance Claim	No claim to be made
Other Units	Remained stable and continued as usual

The update was filed by Dharamvir Malik, Company Secretary & Compliance Officer, in reference to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.53%	+4.50%	-1.59%	+31.05%	-3.53%	-31.15%

Akums Drugs & Pharma has disclosed that it received an ESG rating of 63 for the Financial Year 2024-25, as intimated to the stock exchanges on 8th May, 2026. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.

ESG Rating Details

The rating was assigned by NSE Sustainability Ratings & Analytics Limited (NSE Sustainability), a subsidiary of NSE Indices Limited and a registered ESG Rating Provider. The company has clarified that it did not engage NSE Sustainability for this rating, and the assessment was voluntarily conducted based on publicly available information.

Key details of the ESG rating disclosure are summarised below:

Parameter:	Details
ESG Rating:	63
Financial Year:	2024-25
Rating Date:	7th May, 2026
Rating Agency:	NSE Sustainability Ratings & Analytics Limited
Agency Type:	Registered ESG Rating Provider
Basis of Rating:	Publicly available information
Company Engagement:	Not engaged by the company

Regulatory Disclosure

The intimation was filed by Dharamvir Malik, Company Secretary & Compliance Officer of Akums Drugs and Pharmaceuticals Limited, on 8th May, 2026. The disclosure was addressed to the Listing Departments of both the National Stock Exchange of India Ltd. and BSE Limited, in compliance with applicable SEBI regulations. The full ESG rating is accessible on the NSE Sustainability platform at the link provided in the official communication.